Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 73 | ECE2021 | Next issue

European Congress of Endocrinology 2021

22 May 2021 - 26 May 2021

Card image cap
The European Congress of Endocrinology provides a global platform for the international endocrine community to discuss the latest advances in the field.

Oral Communications

Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg

ea0073oc11.1 | Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg | ECE2021

Circulating cell-free DNA for prognostication and disease surveillance in adrenocortical carcinoma

Smith Gabrielle , Lippert Juliane , Altieri Barbara , Elhassan Yasir , Laura-Sophie Landwehr , Prete Alessandro , Appenzeller Silke , Chortis Vasileios , Steinhauer Sonja , Asia Miriam , Sutcliffe Robert , Whalley Celina , Arlt Wiebke , Fassnacht Martin , Ronchi Cristina

BackgroundAdrenocortical Carcinoma (ACC) is a rare aggressive cancer with a heterogeneous behaviour. Disease surveillance relies on frequent imaging, which has limited sensitivity and results in significant radiation exposure. Aim of the study was to investigate the role of circulating cell-free DNA (ccfDNA) as a biomarker for prognostication and disease monitoring in ACC.MethodsccfDNA was extracted from 1&#8...

ea0073oc11.2 | Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg | ECE2021

Extensive preclinical screening of chemotherapeutic agents and molecular targeted Inhibitors reveals potent combinatory treatment for adrenocortical carcinoma (ACC)

Bothou Christina , Sharma Ashish , Shapiro Igor , Adrian Oo , Kim Baek , Beuschlein Felix , Perge Pal , Igaz Peter , Ronchi Cristina L. , Hantel Constanze

Current systemic treatment options for patients with ACCs are far from being satisfactory. DNA damage/repair mechanisms, which involve e.g. ATM/ATR-signalling or RRM1/RRM2 encoded ribonucleotide reductase (RNR) activation commonly contribute to drug resistance. Moreover, also the regulation of RRM2b, the p53-induced alternative to RRM2, is of unclear importance for ACC. Upon extensive drug screening, including a large panel of classical chemotherapies (doxorubicin, etoposide, ...

ea0073oc11.3 | Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg | ECE2021

Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma (ACC)

Kimpel Otilia , Paul Schindler , Bülent Polat , Megerle Felix , Haak Harm R. , Pittaway James , Quinkler Marcus , Matthias Kroiss , Fassnacht Martin

BackgroundThe ESE-ENSAT guidelines emphasize the role of local therapies and suggest radiotherapy (RT) as an individualized treatment in patients with advanced ACC. However, the evidence for this recommendation is very low. The aim of this study was to retrospectively investigate the efficacy and tolerance of radiation therapy in advanced ACC.MethodsWe screened all patients in five European reference centers ...

ea0073oc11.4 | Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg | ECE2021

The management of post-operative recurrences in patients with adrenocortical carcinoma (ACC): The experience of San Luigi Hospital

Calabrese Anna , Puglisi Soraya , Basile Vittoria , Perotti Paola , Berchialla Paola , Pia Anna , Reimondo Giuseppe , Terzolo Massimo

BackgroundThe management of post-operative recurrences of ACC remains controversial, although the current guidelines recommend a surgical approach whenever feasible with radical intent.AimThe aim of our study was to evaluate retrospectively the management of recurrences in patients with ACC. We collected data of 106 patients with ACC followed at the San Luigi Hospital for the management of recurrence. Median ...

ea0073oc11.5 | Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg | ECE2021

Results of the ADIUVO trial, the first randomized study on post-operative adjuvant mitotane in patients with adrenocortical carcinoma

Terzolo Massimo , Fassnacht Martin , Perotti Paola , Libè Rossella , Lacroix Andre , Kastelan Darko , R. Haak Harm , Arlt Wiebke , Loli Paola , Decoudier Benedicte , Lasolle Hélène , Bancos Irina , Quinkler Marcus , Barisson Villares Fragoso Maria Candida , Canu Letizia , Puglisi Soraya , Calabrese Anna , Kroiss Matthias , Dusek Tina , Bourdeau Isabelle , Baudin Eric , Berchialla Paola , Beuschlein Felix , Bertherat Jerome , Berruti Alfredo

BackgroundThe ESE-ENSAT guidelines suggest adjuvant mitotane for patients with adrenocortical carcinoma (ACC) at high risk of recurrence following radical surgery. This indication has a limited evidence base, lacking results from randomized controlled trials. No suggestion is available in low-risk patients, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane (MIT) treatm...

ea0073oc11.6 | Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg | ECE2021

Investigating the role of cholesterol and lipid trafficking in mitotane resistance in adrenocortical carcinoma

Warde Kate , Yi Jan Lim , Beuschlein Felix , Constanze Hantel , Conall Dennedy Michael

IntroductionAdrenocortical Carcinoma (ACC) is a rare aggressive cancer which carries a poor prognosis. Adjuvant mitotane improves survival but is limited by poor response rates and resistance following tumour recurrence. Mitotane’s efficacy has been attributed to intracellular accumulation of toxic free cholesterol (FC) predominantly through inhibition of cholesterol storage through SOAT1. Yet SOAT1 specific inhibitors demonstrate inferior efficacy ...